Cosmetic outcome one, two, three and four years after intra-operative radiotherapy compared with external beam radiotherapy: An objective assessment of patients from a randomised controlled trial

2012 ◽  
Vol 38 (5) ◽  
pp. 440
Author(s):  
Mohammed Keshtgar ◽  
Norman Williams ◽  
Tammy Corica ◽  
Christobel Saunders ◽  
Max Bulsara ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
External Beam Radiotherapy ◽  
Objective Assessment ◽  
Cosmetic Outcome ◽  
External Beam ◽  
Randomised Controlled

scholarly journals Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial

2013 ◽  
Vol 140 (3) ◽  
pp. 519-525 ◽  
Author(s):  
Mohammed R. S. Keshtgar ◽  
Norman R. Williams ◽  
Max Bulsara ◽  
Christobel Saunders ◽  
Henrik Flyger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Objective Assessment ◽  
Intraoperative Radiotherapy ◽  
Cosmetic Outcome ◽  
Randomised Controlled

Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: An objective assessment of patients from a randomized controlled trial.

2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 94-94
Author(s):  
M. R. Keshtgar ◽  
N. R. Williams ◽  
T. Corica ◽  
C. Saunders ◽  
M. Bulsara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Controlled Trial ◽  
Tumour Size ◽  
External Beam Radiotherapy ◽  
Objective Assessment ◽  
Intraoperative Radiotherapy ◽  
Cosmetic Outcome ◽  
External Beam ◽  
Randomized Controlled

94 Background: The randomized controlled TARGIT Trial was designed to determine noninferiority between the novel technique of TARGIT [intra-operative radiotherapy with Intrabeam (Carl Zeiss, Germany)] and conventional external beam radiotherapy (EBRT) in women with early breast cancer. The main outcome objective is risk of local relapse within the treated breast. We report here data from a subprotocol assessing cosmesis in 114 women over 50 years old participating in the TARGIT Trial from one center (Perth, Australia). Methods: Frontal view digital photographs from were assessed, blind to treatment, using specialist software (BCCT.core 2.0, INESC Porto, Portugal) that produces an objective composite score based on symmetry, color, and scar. Data on patient and tumor characteristics were obtained from hospital notes. Statistical analysis was by generalized estimating equations (GEE) on all data, and logistic regression analysis at year 1 only. Results: Photographs were taken at baseline (before surgery) and 1, 2, 3, and 4 years after initial breast-conserving surgery; none of the 114 patients had subsequent breast surgery. Median age at randomization was 62 years (IQR 56 to 68). The composite scores were dichotomized into Excellent and Good (EG), and Fair and Poor (FP). There was a nonsignificant 45% increase in the odds of having an outcome of EG for patients in the TARGIT group relative to the EBRT group (OR=1.45, 95%CI 0.78 – 2.69, p=0.245) after adjusting for tumour size. The results were similar when adjusted for tumor grade and age of the patient. For year 1 there was a statistically significant 2.35 fold increase in the odds of having an outcome of EG for patients in the TARGIT group relative to the EBRT group (OR=2.35, 95%CI 1.02 – 5.45, p=0.047) after adjusting for age of the patient, tumor size, and grade. Conclusions: These results confirm a significantly better cosmetic outcome with TARGIT compared to EBRT in the first year after surgery.

Sign in / Sign up

Export Citation Format

Share Document